|
Corcept Therapeutics Incorporated |
|
|
149 Commonwealth Drive
Menlo Park, CA 94025 USA
phone:(650) 327-3270
fax:650-327-3218
|
|
| Symbol |
CORT |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
7 |
|
|
|
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drugs for the treatment of severe psychiatric and neurological diseases. |
|
| Management |
| Joseph K. Belanoff, M.D., Chief Executive Officer; Robert L. Roe, M.D., President; Fred Kurland, Chief Financial Officer. |
| |
|
|
|
|
|
|
|
| Keywords |
| psychiatric, neurology |
|
|
|
| Description |
|
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Its focus is on the development of drugs for disorders associated with a steroid hormone called cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a broad range of human disorders. |
|
| Products / Services |
The vompany's lead product candidate, CORLUX, modulates the effect of cortisol by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor.
|
|
|
| Status |
| Corcept has been granted fast track status by the United States Food and Drug Administration (FDA) and is preparing to initiate pivotal clinical trials for CORLUX for the treatment of the psychotic features of psychotic major depression (PMD). The Company has also initiated a clinical study to evaluate the safety and efficacy of CORLUX in improving cognition in patients with mild to moderate Alzheimer's disease. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
